Daily non-political popular news in brief.
Cryoablation continues to show good results for kidney cancer patients
11-25-2007 · EurekAlert!A review of 62 Mayo Clinic patients who underwent cryoablation to treat cancerous kidney tumors shows that the patients are cancer free for up to two and a half years after having had the procedure.
Read more »
Keywords: cryoablation, continues, show, good, results, kidney, cancer, patients, continue, result, patient
« Previous | Next »
Similar news on "Cryoablation continues to show good results for kidney cancer patients":
- Cryoablation is a safe procedure for breast cancer patients, early results indicate
05-04-2007 · EurekAlert!
Ultrasound-guided cryoablation of small breast cancer may be a safe procedure associated with minimal morbidity and high patient satisfaction, according to a recent case report by radiologists at the University of Wisconsin Hospital & Clinics in Madison, WI.
Similar news · Read more »
- Pancreatic cancer vaccine halts progression of disease in some patients
04-17-2007 · EurekAlert!
A dendritic cell-based therapeutic vaccine for pancreatic cancer developed by researchers at the University of Pittsburgh School of Medicine has successfully stalled the disease from progressing in a handful of patients three years post-vaccination. The results, part of a press briefing on cancer vaccines held at the annual meeting of the American Association of Cancer Research, provide promising evidence that the vaccine can trigger a patient's own immune system to rally against pancreatic cancer.
Similar news · Read more »
- Cryoablation -- A new treatment option for some kidney tumor patients
03-28-2007 · EurekAlert!
Mayo Clinic researchers report that freezing kidney tumors through percutaneous cryoablation shows promise for patients who are not good candidates for surgery.
Similar news · Read more »
- Jefferson scientists show gene reverts cancer genes to normal, predicts breast cancer prognosis
10-31-2006 · EurekAlert!
Scientists have shown that the activity of a gene that commandeers other cancer-causing genes, returning them to normal, can predict the prognosis of an individual with breast cancer. They looked at cancer cells from more than 2,000 breast cancer patients and found that this commandeering or "organizing" ability is increasingly lost in cancer cells and associated with the progression of disease. The more the gene is expressed in breast cancer, the better the patient did.
Similar news · Read more »
- Jefferson researchers show chemotherapy and radiation together extend lung cancer patients' lives
11-09-2007 · EurekAlert!
Chemotherapy given at the same time as radiation therapy can help patients with a certain type of lung cancer live nearly 50 percent longer than they might have otherwise if the same treatment was given differently, according to an international team’s analysis of several trial results.
Similar news · Read more »
- Penn's Abramson Cancer Center part of major phase III study for myeloma
11-21-2007 · EurekAlert!
Researchers from the UPenn's Abramson Cancer Center announced today that findings from two international clinical trials show unprecedented survival for patients with myeloma, a cancer the blood-making cells of bone marrow. Findings show that with the oral drug lenalidomide, in combination with dexamethasone, patients significantly improved by all measures where previous treatments had failed -- including a median survival of nearly three years -- the longest median survival known for this difficult to treat patient group.
Similar news · Read more »
- Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia
12-09-2007 · EurekAlert!
Two drugs approved for use as second line therapy for chronic myelogenous leukemia are showing promising results as frontline therapy for newly diagnosed patients in two clinical trials, research teams led by scientists at the University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.
Similar news · Read more »
- Early Phase II results show bosutinib safe, effective for CML
12-11-2007 · EurekAlert!
A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at the University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting of the American Society of Hematology.
Similar news · Read more »
- Annals of Internal Medicine tip sheet for March 20, 2007
03-19-2007 · EurekAlert!
The following articles are featured in the upcoming Annals of Internal Medicine: "Flexible Use of Drugs with Close Patient Follow-up Can Successfully Control Rheumatoid Arthritis;" "Osteoporosis Drug Strengthens Bones in Men with Prostate Cancer," and "Experts Show Physicians How to Initiate and Carry Through Timely and Effective Discussions about Hospice with Dying Patients."
Similar news · Read more »
- Sutent achieves first line EAU approval for kidney cancer
03-22-2007 · EurekAlert!
Sutent (sunitinib malate) has received a European Association of Urology recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma.
Similar news · Read more »
